抗辐射性
DNA损伤
癌症研究
辐射敏感性
蛋白质精氨酸甲基转移酶5
生物
DNA
医学
放射治疗
细胞培养
基因
甲基转移酶
遗传学
内科学
甲基化
作者
Kan Jiang,Xin Yin,Qingyi Zhang,Jie Yin,Qiuying Tang,Mengyou Xu,Lingyun Wu,Yifan Shen,Ziyang Zhou,Hao Yu,Senxiang Yan
出处
期刊:Redox biology
[Elsevier BV]
日期:2023-02-02
卷期号:60: 102626-102626
被引量:101
标识
DOI:10.1016/j.redox.2023.102626
摘要
Radioresistance is the major reason for the failure of radiotherapy in esophageal squamous cell carcinoma (ESCC). Previous evidence indicated that stanniocalcin 2 (STC2) participates in various biological processes of malignant tumors. However, researches on its effect on radioresistance in cancers are limited. In this study, STC2 was screened out by RNA-sequencing and bioinformatics analyses as a potential prognosis predictor of ESCC radiosensitivity and then was determined to facilitate radioresistance. We found that STC2 expression is increased in ESCC tissues compared to adjacent normal tissues, and a higher level of STC2 is associated with poor prognosis. Also, STC2 mRNA and protein expression levels were higher in radioresistant cells than in their parental cells. Further investigation revealed that STC2 could interact with protein methyltransferase 5 (PRMT5) and activate PRMT5, thus leading to the increased expression of symmetric dimethylation of histone H4 on Arg 3 (H4R3me2s). Mechanistically, STC2 can promote DDR through the homologous recombination and non-homologous end joining pathways by activating PRMT5. Meanwhile, STC2 can participate in SLC7A11-mediated ferroptosis in a PRMT5-dependent manner. Finally, these results were validated through in vivo experiments. These findings uncovered that STC2 might be an attractive therapeutic target to overcome ESCC radioresistance.
科研通智能强力驱动
Strongly Powered by AbleSci AI